Westside Investment Management Inc. Increases Stock Holdings in enVVeno Medical Corporation (NASDAQ:NVNO)

Westside Investment Management Inc. boosted its stake in shares of enVVeno Medical Corporation (NASDAQ:NVNO) by 132.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 205,025 shares of the company’s stock after buying an additional 116,650 shares during the period. Westside Investment Management Inc.’s holdings in enVVeno Medical were worth $619,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Geode Capital Management LLC raised its stake in shares of enVVeno Medical by 7.8% in the third quarter. Geode Capital Management LLC now owns 150,676 shares of the company’s stock valued at $506,000 after acquiring an additional 10,902 shares during the period. Corsair Capital Management L.P. purchased a new position in shares of enVVeno Medical during the 3rd quarter worth about $390,000. Maven Securities LTD bought a new position in enVVeno Medical during the 3rd quarter valued at about $295,000. Hohimer Wealth Management LLC purchased a new stake in enVVeno Medical in the 3rd quarter worth about $286,000. Finally, Fermata Advisors LLC lifted its stake in enVVeno Medical by 18.1% in the fourth quarter. Fermata Advisors LLC now owns 35,706 shares of the company’s stock worth $108,000 after purchasing an additional 5,481 shares during the last quarter. 34.71% of the stock is currently owned by institutional investors.

enVVeno Medical Stock Performance

NVNO opened at $3.52 on Wednesday. The stock’s 50 day moving average price is $3.12 and its 200-day moving average price is $4.08. enVVeno Medical Corporation has a one year low of $2.45 and a one year high of $6.97. The stock has a market cap of $61.65 million, a price-to-earnings ratio of -2.73 and a beta of 1.21.

enVVeno Medical (NASDAQ:NVNO) last announced its quarterly earnings data on Thursday, October 31st. The company reported ($0.35) EPS for the quarter, missing the consensus estimate of ($0.33) by ($0.02). As a group, analysts predict that enVVeno Medical Corporation will post -1.3 earnings per share for the current fiscal year.

About enVVeno Medical

enVVeno Medical Corporation (Nasdaq: NVNO) is an medical device company focused on the development of innovative bioprosthetic (tissue-based) devices to improve the standard of care in the treatment of venous disease. The company’s lead product, the VenoValve®️, is a first-in-class, surgical implant being developed for the treatment of severe deep venous Chronic Venous Insufficiency (CVI).